Journal of Polymer ScienceVolume 61, Issue 18 p. i-i COVER IMAGEFree Access Cover Image, Volume First published: 15 September 2023 https://doi.org/10.1002/pol.20230610AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text full-text accessPlease review our Terms and Conditions Use check box below share version article.I have read accep...

BACKGROUND Vascular endothelial growth factor (VEGF) inhibition is a valid therapeutic approach in renal cell carcinoma. Therefore, an investigation of the combination treatment of the humanised anti-VEGF monoclonal antibody bevacizumab with interferon alfa was warranted. METHODS In a multicentre, randomised, double-blind, phase III trial, 649 patients with previously untreated metastatic ren...

BACKGROUND AND PURPOSE Activated protein C (APC), a protease with anticoagulant and cytoprotective activities, protects neurons and endothelium from ischemic injury. Drotrecogin-alfa activated, a hyperanticoagulant form of human recombinant APC, is currently being studied in patients with ischemic stroke. How changes in APC anticoagulant activity influence APC's neuroprotection and risk for ble...

BACKGROUND Patients with systolic heart failure and anemia have worse symptoms, functional capacity, and outcomes than those without anemia. We evaluated the effects of darbepoetin alfa on clinical outcomes in patients with systolic heart failure and anemia. METHODS In this randomized, double-blind trial, we assigned 2278 patients with systolic heart failure and mild-to-moderate anemia (hemog...

BACKGROUND Drotrecogin alfa (activated), or recombinant human activated protein C, has antithrombotic, antiinflammatory, and profibrinolytic properties. In a previous study, drotrecogin alfa activated produced dose-dependent reductions in the levels of markers of coagulation and inflammation in patients with severe sepsis. In this phase 3 trial, we assessed whether treatment with drotrecogin al...

Sir, I would like to thank Lars Weiss for his interesting comments regarding my Editorial Comment [1] from over a year ago! However, I do have some difficulty accepting one or two of his arguments. While one cannot completely exclude the possibility of different pharmacodynamics between epoetin alfa and epoetin beta, I feel it is unlikely that a difference in intravenous (i.v.) half-life of 6.8...

Extended Abstract Calcium carbonate (CaCO3) is one of the most abundant biominerals in nature and investigated at the laboratories, as well. CaCO3 has abundant industrial applications such as filler materials, bleaching agents, opacity reducer, paper filling, and biomedical applications such as drug delivery and orthopaedic– traumatology. For example, carbonate apatite acts as bioceramic implan...

Gaucher disease (GD) is a lysosomal storage disorder; symptomatic patients with type 1 GD need long-term disease-specific therapy of which the standard of care has been enzyme replacement therapy (ERT). Thirty-eight of 40 patients (aged 9-71 years) clinically stable on ERT with imiglucerase, safely switched to a comparable dose of velaglucerase alfa (units/kg) during TKT034, a 12-month, open-la...

Taliglucerase alfa is an enzyme replacement therapy (ERT) approved for treatment of adult and paediatric patients with Type 1 Gaucher disease (GD) in several countries and the first plant cell-expressed recombinant therapeutic protein approved by the US Food and Drug Administration for humans. Here, we review the findings across six key taliglucerase alfa clinical studies. A total of 33 treatme...